Charles River Laboratories Publishes 2023 Corporate Citizenship Report

Published: 2024-03-27 08:03:05 ET CRL

ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet.

“The work we do at Charles River today extends beyond science. With more than 21,000 employees, our collective efforts are powerful, and our influence is transforming the biopharmaceutical industry to make a difference for both patients and the planet,” said James C. Foster, Chair, President, and Chief Executive Officer of Charles River. “We are proud of the progress we have made on our ESG commitments while working together to develop treatments that can save lives.”

Published every two years, the report highlights Charles River’s progress towards its ambitious Corporate Citizenship goals, as well as new milestones and accomplishments:

Accelerate Life-Saving Therapies

Charles River is committed to bringing effective medicines to patients safely and as quickly as possible and continues to be a trusted, global scientific partner of choice:

Lead with Integrity

Making a positive impact on patients, animals in its care, and communities where employees work is central to Charles River’s ethos. During the 2022-2023 period, the Company:

Inspire our People

Charles River is committed to providing an exceptional employee experience in which its people can learn, grow, and make an impact. Employee-focused initiatives include:

Protect our Planet

Charles River operates responsibly and promotes a sustainable future in the communities where the Company operates. Working towards its environmental goals, Charles River:

The 2023 Corporate Citizenship Report was prepared in accordance with the latest Global Reporting Initiative (GRI) Universal Standards, as well as the Sustainability Accounting Standards Board (SASB) Biotechnology and Pharmaceuticals Standard. The report is also aligned with relevant U.N. Sustainable Development Goals (UNSDGs) and recommendations set out by the Task Force on Climate-related Financial Disclosures (TCFD). The TCFD report will be available later in 2024 at www.criver.com.

Visit the Corporate Citizenship section of Charles River’s website to read the 2023 Corporate Citizenship Report in its entirety and learn more about the Company’s ESG disclosures.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327700198/en/